Thrivent Financial for Lutherans Sells 8,027 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Thrivent Financial for Lutherans lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 7.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 100,231 shares of the company's stock after selling 8,027 shares during the period. Thrivent Financial for Lutherans owned about 0.12% of IDEXX Laboratories worth $41,439,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in IDXX. Flossbach Von Storch SE increased its stake in shares of IDEXX Laboratories by 5,439.3% in the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock valued at $195,696,000 after buying an additional 464,791 shares in the last quarter. William Blair Investment Management LLC lifted its stake in shares of IDEXX Laboratories by 701.6% in the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock valued at $174,527,000 after purchasing an additional 369,471 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of IDEXX Laboratories by 265.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock worth $179,867,000 after purchasing an additional 316,048 shares during the last quarter. Seilern Investment Management Ltd acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth $113,104,000. Finally, Vontobel Holding Ltd. lifted its stake in IDEXX Laboratories by 90.1% in the fourth quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company's stock valued at $173,051,000 after buying an additional 198,404 shares during the period. 87.84% of the stock is owned by institutional investors.

Remove Ads

IDEXX Laboratories Stock Up 0.6 %

Shares of NASDAQ IDXX traded up $2.61 during midday trading on Monday, reaching $423.60. The company's stock had a trading volume of 616,827 shares, compared to its average volume of 552,334. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $548.88. The stock has a 50 day simple moving average of $437.36 and a 200-day simple moving average of $444.76. The stock has a market capitalization of $34.34 billion, a price-to-earnings ratio of 39.70, a PEG ratio of 3.41 and a beta of 1.39.

Insider Activity

In other news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a research note on Monday, December 2nd. StockNews.com lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, March 15th. Morgan Stanley reduced their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Piper Sandler upped their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Finally, Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.